Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels.
Eli Lilly Has a Major Problem With Its Weight Loss Drugs Zepbound and Mounjaro
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent quarterly sales.
Hong Kong approves celebrity weight-loss drug, but experts say it’s not just to look good
The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned against using it for cosmetic purposes without a doctor’s prescription. US drug giant Eli Lilly announced last month that Mounjaro,
Eli Lilly plans to begin advertising weight-loss drug Zepbound
Eli Lilly ( LLY) is planning to advertise its blockbuster weight loss drug, Zepbound, for the first time next month. Despite investor and industry recognition of the branded GLP-1 drug, "unaided awareness of Zepbound ... is actually not very high," CEO David Ricks said on an earnings call Wednesday morning.
FDA approves a new weight loss drug, Zepbound from Eli Lilly
The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
FDA adds new warning to weight loss drugs including Wegovy
The U.S. Food and Drug Administration has added a new warning to drugs including Ozempic and Wegovy, cautioning that patients taking the drugs may be at a higher risk of inhaling gastric contents into their lungs while under anesthesia.
FDA adds new warning to popular weight loss drugs
The Food and Drug Administration has updated labels for popular weight loss drugs like Ozempic and Wegovy.
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
Reuters13d
Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News
Oct 27 (Reuters) - Eli Lilly (LLY.N), opens new tab expects to start selling its weight-loss ... Tirzepatide is the ...
Is Eli Lilly Stock a Buy?
However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are ...
STAT12d
Eli Lilly hits rare stumble, as sales and earnings disappoint
Eli Lilly's quarterly sales and earnings underperformed, a rare stumble for the company and its weight loss drug ...
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...